Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESTA NASDAQ:NVCR NASDAQ:RXST NASDAQ:SSII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$34.80-3.2%$40.82$26.56▼$50.85$1.04B0.83352,613 shs807,937 shsNVCRNovoCure$11.13-3.3%$15.85$10.91▼$34.13$1.29B0.612.07 million shs1.37 million shsRXSTRxSight$7.19-7.7%$11.09$6.32▼$58.23$316.56M1.161.19 million shs1.66 million shsSSIISS Innovations International$6.77+1.3%$5.88$0.32▼$22.42$1.29BN/A128,308 shs33,187 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-3.23%-15.82%-22.77%+2.32%-2.14%NVCRNovoCure-3.30%-1.68%-38.81%-35.96%-42.06%RXSTRxSight-7.70%-7.82%-9.56%-45.24%-84.45%SSIISS Innovations International+1.35%+9.19%+43.13%-32.90%+676,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESTAEstablishment Labs1.9245 of 5 stars3.40.00.00.02.32.50.6NVCRNovoCure4.5041 of 5 stars3.35.00.04.53.23.30.0RXSTRxSight3.1251 of 5 stars4.04.00.00.01.71.70.6SSIISS Innovations InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESTAEstablishment Labs 2.80Moderate Buy$55.8060.34% UpsideNVCRNovoCure 2.57Moderate Buy$28.79158.63% UpsideRXSTRxSight 1.91Reduce$10.0039.08% UpsideSSIISS Innovations International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RXST, NVCR, SSII, and ESTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.008/8/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$9.00 ➝ $8.008/8/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $11.007/25/2025NVCRNovoCureWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$40.00 ➝ $14.507/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/15/2025RXSTRxSightMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.007/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESTAEstablishment Labs$166.02M6.06N/AN/A$1.90 per share18.32NVCRNovoCure$605.22M2.06N/AN/A$3.13 per share3.56RXSTRxSight$139.93M2.09N/AN/A$6.98 per share1.03SSIISS Innovations International$20.65M63.47N/AN/A$0.22 per share30.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-49.89%-199.06%-25.71%N/ANVCRNovoCure-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%N/ARXSTRxSight-$27.45M-$0.67N/AN/AN/A-21.93%-11.55%-10.27%N/ASSIISS Innovations International-$19.15MN/A0.00∞N/A-40.20%-40.41%-20.80%N/ALatest RXST, NVCR, SSII, and ESTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million8/7/2025Guidance UpdateRXSTRxSight-$0.04-$0.08-$0.04-$0.29$39.78 million$33.64 million7/24/2025Q2 2025NVCRNovoCure-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESTAEstablishment LabsN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESTAEstablishment Labs5.723.362.05NVCRNovoCure0.281.451.39RXSTRxSightN/A12.6811.65SSIISS Innovations InternationalN/A2.592.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESTAEstablishment Labs72.91%NVCRNovoCure84.61%RXSTRxSight78.78%SSIISS Innovations InternationalN/AInsider OwnershipCompanyInsider OwnershipESTAEstablishment Labs11.09%NVCRNovoCure5.52%RXSTRxSight9.57%SSIISS Innovations InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableNVCRNovoCure1,488111.80 million105.63 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableSSIISS Innovations International4193.59 millionN/AN/ARXST, NVCR, SSII, and ESTA HeadlinesRecent News About These CompaniesSs Innovations (SSII) Q2 Revenue Up 122%August 8 at 9:11 AM | aol.comASS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7 at 8:53 AM | prismmediawire.comPSS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7 at 8:45 AM | globenewswire.comSS Innovations International (NASDAQ:SSII) Shares Gap Up - Should You Buy?August 5, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Up - Still a Buy?July 25, 2025 | marketbeat.comSS Innovations Announces Completion of World’s First Intercontinental Robotic Cardiac TelesurgeryJuly 23, 2025 | finance.yahoo.comSS Innovations International (NASDAQ:SSII) Shares Gap Down - Here's WhyJuly 22, 2025 | marketbeat.comSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | globenewswire.comSS Innovations International (NASDAQ:SSII) Sees Large Volume Increase - Here's WhyJuly 18, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Down 7.7% - Should You Sell?July 18, 2025 | marketbeat.comSSII - SS Innovations International Inc Ownership | MorningstarJuly 17, 2025 | morningstar.comMSS Innovations International (NASDAQ:SSII) Shares Up 7.1% - Still a Buy?July 16, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Up - Here's What HappenedJuly 15, 2025 | marketbeat.comSS Innovations Surpasses Milestone of 100 Installations of the SSi Mantra Surgical Robotic SystemJuly 15, 2025 | prismmediawire.comPSS Innovations International (NASDAQ:SSII) Shares Gap Down - Time to Sell?July 11, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Up 13.7% - Here's What HappenedJuly 10, 2025 | marketbeat.comSS Innovations Announces Completion of World's First Robotic Telesurgery for Weight Loss with the Company's SSi Mantra 3 Surgical Robotic SystemJuly 10, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Robotic Telesurgery for Weight Loss with the Company's SSi Mantra 3 Surgical Robotic SystemJuly 10, 2025 | globenewswire.comSS Innovations: A Speculative Bet On Robotic SurgeriesJune 19, 2025 | seekingalpha.comSS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company's SSi Mantra 3 Surgical Robotic SystemJune 16, 2025 | prismmediawire.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXST, NVCR, SSII, and ESTA Company DescriptionsEstablishment Labs NASDAQ:ESTA$34.80 -1.16 (-3.23%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$35.70 +0.90 (+2.60%) As of 08/8/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.NovoCure NASDAQ:NVCR$11.13 -0.38 (-3.30%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.38 +0.24 (+2.20%) As of 08/8/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.RxSight NASDAQ:RXST$7.19 -0.60 (-7.70%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.19 0.00 (0.00%) As of 08/8/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SS Innovations International NASDAQ:SSII$6.77 +0.09 (+1.35%) As of 08/8/2025 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
